Current Pain and Headache Reports

, Volume 9, Issue 6, pp 377–389

An update on nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors

  • Gary W. Williams
Article

Abstract

Selective inhibitors of the cyclooxygenase-2 enzyme were developed to treat pain and inflammation while reducing the risk of the serious gastrointestinal side effects seen with nonselective nonsteroidal anti-inflammatory drugs (NSAIDs). The results of several clinical trials have demonstrated an apparent increased risk of serious cardiovascular events in patients taking the COX-2-selective inhibitors. Although the risk was observed originally with trials conducted with rofecoxib, it was attributed generally to the entire class of COX-2-selective drugs based on a similar mechanism of action and a hypothesis that predicted the possibility of a prothrombotic effect of the drugs compared with nonselective NSAIDs. Subsequent studies have demonstrated that elevated cardiovascular risk is not limited to the use of COX-2-specific inhibitors. An increase in cardiovascular risk actually has been seen with antiinflammatory drugs of the NSAID class, regardless of whether they are selective or nonselective inhibitors. The US Food and Drug Administration has recommended that all such drugs carry a black box warning for gastrointestinal and cardiovascular risks.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Fries JF, Williams CA, Bloch DA, et al.: Nonsteroidal antiinflammatory drug-associated gastropathy: incidence and risk factor models. Gastroenterology 1989, 96(suppl 2):647–655. The VIGOR trial. Gastrointestinal safety advantage of rofecoxib was found for primary and secondary endpoints, allowing a claim in the package insert for rofecoxib compared with naproxen. The importance of the paper now related to the fourfold elevated cardiovascular risk on rofecoxib. A cardiovascular adjudication committee was in place and published data represent the adjudicated rather than the investigator-reported cardiovascular events. The difference in cardiovascular events was later revised to fivefold at the FDA Advisory Committee Meeting in 2001 by Villalba after review of the study documents.PubMedGoogle Scholar
  2. 2.
    Bresalier RS, Sandler RS, Quan H, et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352:1092–1102. The CLASS trial failed to meet its primary gastrointestinal endpoint, but did reach statistical significance for the combination of gastrointestinal complications and symptomatic ulcers favoring the celecoxib treatment group compared with the NSAID-treated group. Aspirin use reached 22% at end of enrollment. Investigator-reported serious thromboembolic cardiovascular events for celecoxib, diclofenac, and ibuprofen were 1.2%, 1.4%, and 1.1%, respectively.PubMedCrossRefGoogle Scholar
  3. 3.
    Solomon SD, McMurray JJV, Pfeffer MA, et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071–1080. The APPROVe (Adenomatous Polyp Prevention on Vioxx) trial was a long-term, multicenter, randomized, placebo-controlled, double-blind trial designed to determine the effect of 3 years of treatment with 25 mg of rofecoxib on the risk of recurrent neoplastic polyps of the large bowel in patients with a history of colorectal adenomas [46]. The difference between the rofecoxib and placebo groups in the incidence of thrombotic events was evident in the second 18 months of the study. Compared with the placebo group, the rofecoxib group had higher percentages of patients with hypertension-related events and edema-related events. The increased cardiovascular risk in this trial resulted in the manufacturer’s voluntary withdrawal of rofecoxib from the market on September 30, 2004.PubMedCrossRefGoogle Scholar
  4. 4.
    Nussmeier NA, Whelton AA, Brown MT, et al.: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005, 352:1081–1091. The Adenoma Prevention with Celecoxib trial sponsored by the National Cancer Institute was terminated early due to findings that celecoxib use at 200 and 400 mg twice daily was associated with a dose-related increase in the composite endpoint of death from cardiovascular causes, myocardial infarction, stroke, or heart failure compared with placebo.PubMedCrossRefGoogle Scholar
  5. 5.
    www.fda.gov/ohrms/dockets/ac/05/minutes/2005-4090M1_Final.htm. Accessed August 2, 2005. The CABG II trial; patients treated with parecoxib/valdecoxib were significantly (P = 0.03) more likely to suffer a cardiovascular thromboembolic event (2.0%) than were patients receiving placebo/placebo (0.5%). Placebo/valdecoxib treatment also was associated with a higher incidence of cardiovascular thromboembolic events versus placebo treatment, but this difference did not reach statistical significance. The FDA Advisory Committee discussed the possibility that the risk may be related to the inhibition of prostacyclin and that an increase in events may be expected in patients in this vulnerable setting placed on COX-2-selective or nonselective NSAIDs. The FDA has determined that all prescription NSAIDs and celecoxib (the remaining marketed COX-2) will now carry contraindications in patients undergoing CABG surgery.Google Scholar
  6. 6.
    Food and Drug Administration. http://www.fda.gov/cder/ drug/infopage/COX2/NSAIDdecisionMemo.pdf. April 6, 2005. Accessed August 2, 2005. High-risk patients with a history of bleeding from a documented gastrointestinal ulcer. Following treatment of the ulcer, endoscopic documentation of healing and eradication of H. Pylori infection if present, patients who required anti-inflammatory therapy were randomized to a nonselective NSAID, diclofenac plus the PPI omeprozole, or celelcoxib 200 mg twice daily without a PPI. The rate of recurrent ulceration at 6 months was high with either option and there was no statistical advantage of one treatment approach over the other, although there were numerically fewer documented episodes of re-bleeding in the patients randomized to the COX-2-selective agent celecoxib without a PPI.Google Scholar
  7. 7.
    Vane JR, Bakhle YS, Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998, 38:97–120. A good review of the cardiovascular data through 2002, including an in-depth discussion of the conflicting studies regarding the putative cardioprotective effect of naproxen.PubMedCrossRefGoogle Scholar
  8. 8.
    Data on File, G.D. Searle and Co.Google Scholar
  9. 9.
    Williams GW, Ettlinger RE, Ruderman EM, et al.: Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: a randomized, controlled trial. J Clin Rheumatol 2000, 6:65–74.CrossRefPubMedGoogle Scholar
  10. 10.
    Williams GW, Hubbard RC, Yu SS, et al.: Comparison of oncedaily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee. Clin Ther 2001, 23:213–227.PubMedCrossRefGoogle Scholar
  11. 11.
    Simon LS, Weaver AL, Graham DY, et al.: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized, controlled trial. JAMA 1999, 282:1921–1928.PubMedCrossRefGoogle Scholar
  12. 12.
    Makarowski W, Zhao WW, Bevirt T, Recker DP: Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage 2002, 10:290–296.PubMedCrossRefGoogle Scholar
  13. 13.
    McKenna F, Borenstein D, Wendt H, et al.: Celecoxib versus diclofenac in the management of osteoarthritis of the knee: a placebo-controlled, randomised, double-blind comparison. Scand J Rheumatol 2001, 30:11–18.PubMedCrossRefGoogle Scholar
  14. 14.
    Cannon GW, Caldwell JR, Holt P, et al.: Rofecoxib, a specific inhibitor of cyclooxygenase 2, with efficacy comparable with that of diclofenac sodium: results of a 1-year, randomized, clinical trial in patients with osteoarthritis of the hip and knee. Arthritis Rheum 2000, 43:978–987.PubMedCrossRefGoogle Scholar
  15. 15.
    Goldstein JL, Silverstein FE, Agrawal NM, et al.: Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000, 95:1681–1690.PubMedCrossRefGoogle Scholar
  16. 16.
    Silverstein FE, Faich G, Goldstein JL, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized, controlled trial. JAMA 2000, 284:1247–1255.PubMedCrossRefGoogle Scholar
  17. 17.
    Bombardier C, Laine L, Reicin A, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000, 343:1520–1528.PubMedCrossRefGoogle Scholar
  18. 18.
    Arthritis Advisory Committee; http://www.fda.gov/ohrms/ dockets/ac/ 03/briefing/3930B1_01_B-TNF.Briefing.pdf. March 4, 2003. Accessed August 2, 2005.Google Scholar
  19. 19.
    Rahme E, Bardou M, Dasqupta K, et al.: Gastrointestinal bleeding associated with concurrent utilization of selective COX-2 inhibitors and aspirin versus non-selective NSAIDs and aspirin. Ann Rheum Dis 2004, 63(suppl 1):522s-523s.Google Scholar
  20. 20.
    Rahme E, Barkun AN, Adam V, et al.: Treatment costs to prevent or treat upper gastrointestinal adverse events associated with NSAIDs. Pharmacoepidemiol Drug Saf 2004, 13:233s-234s.Google Scholar
  21. 21.
    Goldstein JL, Eisen G, Lewis B: Abstract presented at American College of Rheumatology 67th Annual Meeting. Orlando: October 23–26, 2003.Google Scholar
  22. 22.
    Rahme E, Barcon A, Toubouti Y, et al.: Do proton pump inhibitors (PPI) infer additional gastorintesinal protection in patients given celecoxib? A retrospective cohort study. Gastroenterology 2005, 128(suppl2):A24.Google Scholar
  23. 23.
    Chan FK, Hung LC, Suen BY, et al.: Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002, 347:2104–2110.PubMedCrossRefGoogle Scholar
  24. 24.
    Laine L, Connors LG, Reicin A, et al.: Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003, 124:288–292.PubMedCrossRefGoogle Scholar
  25. 25.
    Wilcox CM, Alexander LN, Cotsonis GA, Clark WS: Nonsteroidal anti-inflammatory drugs are associated with both upper and lower gastrointestinal bleeding. Dig Dis Sci 1997, 42:990–997.PubMedCrossRefGoogle Scholar
  26. 26.
    Allison MC, Howatson AG, Torrance CJ, et al.: Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med 1992, 327:749–754.PubMedCrossRefGoogle Scholar
  27. 27.
    Goldstein JL, Eisen GM, Lewis B, et al.: Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005, 3:133–141.PubMedCrossRefGoogle Scholar
  28. 28.
    Weil J, Colin-Jones D, Langman M, et al.: Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995, 310:827–830.PubMedGoogle Scholar
  29. 29.
    Chan FK, Ching JY, Hung LC, et al.: Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005, 352:238–244.PubMedCrossRefGoogle Scholar
  30. 30.
    Whelton A, Fort JG, Puma JA, et al.: Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001, 8:85–95.PubMedCrossRefGoogle Scholar
  31. 31.
    White WB, Kent J, Taylor A, et al.: Effect of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002, 39:929–934.PubMedCrossRefGoogle Scholar
  32. 32.
    Merck & Co, Inc.: VIOXX (rofecoxib) package insert [Pamphlet]. West Point, PA: Merck & Co, Inc; 2001.Google Scholar
  33. 33.
    McAdam BF, Catella-Lawson F, Mardini IA, et al.: Systemic biosynthesis of prostacycline by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999, 96:272–277.PubMedCrossRefGoogle Scholar
  34. 34.
    Cheng Y, Austin SC, Rocca B, et al.: Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002, 296:539–541.PubMedCrossRefGoogle Scholar
  35. 35.
    Strand V, Hochberg MC: The risk of cardiovascular thrombotic events with COX-2 selective inhibitors. Arthritis Rheum 2002, 47:349–355.PubMedCrossRefGoogle Scholar
  36. 36.
    US Food and Drug Administration: Rofecoxib prescribing information label change; April 2002.Google Scholar
  37. 37.
    Ray W, Stein C, Daugherty J, et al.: Cox-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002, 360:1071–1073.PubMedCrossRefGoogle Scholar
  38. 38.
    White WB, Faich G, Borer JS, et al.: Cardiovascular thrombotic events in arthritis trials of the cyclooxygnease-2 inhibitor celecoxib. Am J Card 2003, 92:411–418.PubMedCrossRefGoogle Scholar
  39. 39.
    Chenevard R, Harlimann D, Bechir M: Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003, 107:405–409.PubMedCrossRefGoogle Scholar
  40. 40.
    Title LM, Giddens K, McInerney MM, et al.: Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J Am Coll Cardiol 2003, 42:1747–1753.PubMedCrossRefGoogle Scholar
  41. 41.
    Walter MF, Jacob RF, Day CA, et al.: Sulfone COX-2 inhibitors increase susceptibility of human DL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis 2004, 177:235–243.PubMedCrossRefGoogle Scholar
  42. 42.
    Sotirios Tsimikas MD, Emmanouil S, Brilakis MD, et al.: Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005, 353:46–57.PubMedCrossRefGoogle Scholar
  43. 43.
    Thun MJ, Henley SJ, Patrono C: Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002, 94:252–266.PubMedGoogle Scholar
  44. 44.
    Giovannucci E, Egan KM, Hunter DJ, et al.: Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995, 333:609–614.PubMedCrossRefGoogle Scholar
  45. 45.
    Steinbach G, Lynch PM, Phillips RK, et al.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000, 342:1946–1952.PubMedCrossRefGoogle Scholar
  46. 46.
    Bresalier RS, Sandler RS, Quan H, et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352:1092–1102.PubMedCrossRefGoogle Scholar
  47. 47.
    Solomon SD, McMurray J, Pfeffer MA, Adenoma Prevention with Celecoxib Study Investigators, et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071–1080.PubMedCrossRefGoogle Scholar
  48. 48.
    Levin B: FDA Advisory Committee Meeting. Gaithersburg, MD: February 17, 2005.Google Scholar
  49. 49.
    Ott E, Nussmeier NA, Duke PC, et al.: Efficacy and safety of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003, 125:1481–1492.PubMedCrossRefGoogle Scholar
  50. 50.
    Nussmeier NA, Whelton AA, Brown MT, et al.: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005, 352:1081–1091.PubMedCrossRefGoogle Scholar
  51. 51.
    Solomon DH, Schneeweiss S, Glynn R, et al.: Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004, 109:2068–2073.PubMedCrossRefGoogle Scholar
  52. 52.
    Graham DJ, Campen DH, Cheetham C, et al.: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase-2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005, 365:475–481.PubMedGoogle Scholar
  53. 53.
    Sudbo J: Population-based, nested case-control study of 454 Scandinavian patients diagnosed with oral cancer between 1975 and 2003, and 454 gender- and age-matched controls. Presented at the American Association of Cancer Research Annual Meeting; 2005,Google Scholar
  54. 54.
    Johnsen SP, Larsson H, Tarone RE, et al.: Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005, 165:978–984.PubMedCrossRefGoogle Scholar
  55. 55.
    White WB, Strand V, Roberts R, Whelton A: Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am J Ther 2004, 11:244–250.PubMedCrossRefGoogle Scholar
  56. 56.
    Whelton A, Nussmeier NA, Martineau RJ, et al.: Safety of parecoxib and valdecoxib in the treatment of postoperative pain following coronary artery bypass graft surgery or major general surgery. Presented at American College of Cardiology Annual Scientific Session. Orlando: March 6–9, 2005.Google Scholar
  57. 57.
    Pearson TA, Blair SN, Daniels SR, et al.: AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002, 106:388–391.PubMedCrossRefGoogle Scholar
  58. 58.
    Lévesque LE, Brophy JM, Zhang B: The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study in elderly adults. Ann Intern Med 2005, 142:481–489.PubMedGoogle Scholar
  59. 59.
    Baigent C, Patrono C: Selective cyclooxygenase 2 inhibition, aspirin and cardiovascular disease a reappraisal. Arthritis Rheum 2003, 48:12–20.PubMedCrossRefGoogle Scholar
  60. 60.
    Catella-Lawson F, Muredach PR, Kapoor SC, et al.: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001, 345:1809–1817.PubMedCrossRefGoogle Scholar
  61. 61.
    MacDonald TM, Wei L: Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003, 306:573–574.CrossRefGoogle Scholar
  62. 62.
    Kurth T, Glynn RJ, Walker AM, et al.: Inhibition of clinical benefit of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003, 108:1191–1195.PubMedCrossRefGoogle Scholar
  63. 63.
    Patel TN, Goldberg KC: Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. Arch Intern Med 2004, 164:852–856.PubMedCrossRefGoogle Scholar
  64. 64.
    Hudson M, Baron M, Rahme E, Pilote L: Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction. J Rheumatol 2005, 32:1589–1593.PubMedGoogle Scholar
  65. 65.
    Fischer LM, Schlienger RL, Matter CM, et al.: Current use of nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction. Pharmacotherapy 2005, 25:503–510.PubMedCrossRefGoogle Scholar
  66. 66.
    Solomon DH, Glynn RJ, Levin R, Avorn J: Nonsteroidal antiinflammatory drug use and acute myocardial infarction. Arch Intern Med 2002, 162:1099–1104.PubMedCrossRefGoogle Scholar
  67. 67.
    Watson DJ, Rhodes T, Cai B, Guess HA: Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002, 162:1105–1110.PubMedCrossRefGoogle Scholar
  68. 68.
    Rahme E, Pilote L, LeLorier J: Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002, 162:1111–1115.PubMedCrossRefGoogle Scholar
  69. 69.
    Capone ML, Tacconelli S, Sciulli MG, et al.: Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004, 109:1468–1471.PubMedCrossRefGoogle Scholar
  70. 70.
    NIH Clinical Trials. Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT). http://www.clinical%20trials.gov/ ct/show/NCT00007189?order=1. Accessed August 2, 2005.Google Scholar
  71. 71.
    Konstantinopoulos PA, Lehmann DF: The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding. J Clin Pharmacol 2005, 45:742–750.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • Gary W. Williams
    • 1
  1. 1.Scripps ClinicLa JollaUSA

Personalised recommendations